1/24
05:08 am
ipha
Innate Pharma (NASDAQ:IPHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Innate Pharma (NASDAQ:IPHA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/7
01:00 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
12/22
01:21 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 [Yahoo! Finance]
High
Report
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 [Yahoo! Finance]
12/22
01:00 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
High
Report
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
12/11
01:00 am
ipha
Innate Pharma Releases Its 2026 Financial Calendar
Neutral
Report
Innate Pharma Releases Its 2026 Financial Calendar
11/28
01:16 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 [Yahoo! Finance]
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 [Yahoo! Finance]
11/28
01:00 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
11/17
01:25 am
ipha
Innate Pharma to Present at Jefferies Global Healthcare Conference [Yahoo! Finance]
Low
Report
Innate Pharma to Present at Jefferies Global Healthcare Conference [Yahoo! Finance]
11/17
01:00 am
ipha
Innate Pharma to Present at Jefferies Global Healthcare Conference
Low
Report
Innate Pharma to Present at Jefferies Global Healthcare Conference
11/13
01:06 am
ipha
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results [Yahoo! Finance]
Medium
Report
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results [Yahoo! Finance]
11/13
01:00 am
ipha
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
Medium
Report
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results